How do we improve histone deacetylase inhibitor drug discovery?

References

• Yang XJ, Seto E. Hats and hdacs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26(37):5310–5318.
   PubMed Web of Science ®Google Scholar
• Oppermann U. Why is epigenetics important in understanding the pathogenesis of inflammatory musculoskeletal diseases? Arthritis Res Ther. 2013;15(2):209.
   PubMed Web of Science ®Google Scholar
• Oehme I, Deubzer HE, Wegener D, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009;15(1):91–99.
   PubMed Web of Science ®Google Scholar
• Weichert W, Denkert C, Noske A, et al. Expression of class i histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 2008;10(9):1021–1027.
   PubMed Web of Science ®Google Scholar
• Weichert W, Röske A, Gekeler V, et al. Association of patterns of class i histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9(2):139–148.
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26(37):5541–5552.
   PubMed Web of Science ®Google Scholar
• Schmauss C. An hdac-dependent epigenetic mechanism that enhances the efficacy of the antidepressant drug fluoxetine. Sci Rep. 2015;5: 8171.
   PubMed Web of Science ®Google Scholar
• Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008;7(10):854–868.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Choy ML, Marks PA. Chapter two - mechanisms of resistance to histone deacetylase inhibitors. In: Grant S, editor. Advances in cancer research. Vol. 116. San Diego, USA: Academic Press; 2012. p. 39–86.
   Google Scholar
• Halsall JA, Turner BM. Histone deacetylase inhibitors for cancer therapy: an evolutionarily ancient resistance response may explain their limited success. BioEssays. 2016;38(11):1102–1110.
   PubMed Web of Science ®Google Scholar
• Laschanzky RS, Humphrey LE, Ma J, et al. Selective inhibition of histone deacetylases 1/2/6 in combination with gemcitabine: a promising combination for pancreatic cancer therapy. Cancers (Basel). 2019;11(9):1327.
   Web of Science ®Google Scholar
• Chao M-W, Chang L-H, Tu H-J, et al. Combination treatment strategy for pancreatic cancer involving the novel hdac inhibitor mpt0e028 with a MEK inhibitor beyond k-ras status. Clin Epigenetics. 2019;11(1):85.
   PubMedGoogle Scholar
• Zhang Y, Ishida CT, Ishida W, et al. Combined hdac and bromodomain protein inhibition reprograms tumor cell metabolism and elicits synthetic lethality in glioblastoma. Clin Cancer Res. 2018;24:3941–3954. clincanres.0260.2018.
   Web of Science ®Google Scholar
• Chakravarty S, Bhat UA, Reddy RG, et al. Chapter 25 - histone deacetylase inhibitors and psychiatric disorders. In: Peedicayil J, Grayson DR, Avramopoulos D, editors. Epigenetics in psychiatry. Boston: Academic Press; 2014. p. 515–544.
   Google Scholar
• Guan J-S, Haggarty SJ, Giacometti E, et al. Hdac2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459(7243):55–60.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Morinobu S, Yamamoto S, et al. Vorinostat ameliorates impaired fear extinction possibly via the hippocampal NMDA-camkii pathway in an animal model of posttraumatic stress disorder. Psychopharmacology (Berl). 2013;229(1):51–62.
   PubMed Web of Science ®Google Scholar
• Simões-Pires C, Zwick V, Nurisso A, et al. Hdac6 as a target for neurodegenerative diseases: what makes it different from the other hdacs? Mol Neurodegener. 2013;8(1):7.
   PubMedGoogle Scholar
• Kirschbaum MH, Foon KA, Frankel P, et al. A phase 2 study of belinostat (pxd101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a california cancer consortium study. Leuk Lymphoma. 2014;55(10):2301–2304.
   PubMed Web of Science ®Google Scholar
• Schlimme S, Hauser A-T, Carafa V, et al. Carbamate prodrug concept for hydroxamate hdac inhibitors. ChemMedChem. 2011;6(7):1193–1198.
   PubMed Web of Science ®Google Scholar
• Daniel KB, Sullivan ED, Chen Y, et al. Dual-mode hdac prodrug for covalent modification and subsequent inhibitor release. J Med Chem. 2015;58(11):4812–4821.
   PubMed Web of Science ®Google Scholar
• Zheng S, Guo S, Zhong Q, et al. Biocompatible boron-containing prodrugs of belinostat for the potential treatment of solid tumors. Acs Med Chem Lett. 2018;9(2):149–154.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Li W, Hu X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ace): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(6):806–815.
   PubMed Web of Science ®Google Scholar
• Lamaa D, Lin H-P, Zig L, et al. Design and synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin a-4. J Med Chem. 2018;61(15):6574–6591.
   PubMed Web of Science ®Google Scholar
• Chu-Farseeva Y-Y, Mustafa N, Poulsen A, et al. Design and synthesis of potent dual inhibitors of jak2 and hdac based on fusing the pharmacophores of xl019 and vorinostat. Eur J Med Chem. 2018;158:593–619.
   PubMed Web of Science ®Google Scholar
• He S, Dong G, Li Y, et al. Potent dual bet/hdac inhibitors for efficient treatment of pancreatic cancer. Angewandte Chemie. 2020;59(8):3028–3032.
   Google Scholar
• Luan Y, Li J, Bernatchez JA, et al. Kinase and histone deacetylase hybrid inhibitors for cancer therapy. J Med Chem. 2019;62(7):3171–3183.
   PubMed Web of Science ®Google Scholar
• Cantor DJ, David G. The potential of targeting sin3b and its associated complexes for cancer therapy. Expert Opin Ther Targets. 2017;21(11):1051–1061.
   PubMed Web of Science ®Google Scholar